Treatment with immune checkpoint inhibitors has emerged as a frontline treatment for patients with CRC, mainly targeting cytotoxic T-lymphocyte antigen 4 (CTLA-4) and programed death-1 receptor (PD1) and its ligand PD-L1 (25). This evidence concerns the gene CTLA4 and colorectal carcinoma.